More than 50 companies acquired since 2008
El nivel de acquisitions producidas en el sector de biotecnología en España ha mantenido unos niveles muy estables desde el 2010 hasta el 2013. Este primer semestre del 2014 ha experimentado un repunte con 7 operaciones. Es importante para el sector un buen historial de éxitos para inversores para poder atraer a más capital que financie las empresas biotecnológicas españolas.
The stock market becomes an alternative exit route for investors
Few Spanish companies have gone public in the last few years. Bag since Zeltia was floated on the continuous market in 1991. In 2006 it was Grifols, followed by Almirall and Rovi in 2007. But the emergence of the MAB has enabled smaller biotech companies to access investment to finance the development of their drugs and products. It was the companies Neuron and AB-BIotics that launched the new alternative market in June 2010.
Other related links:
We are currently preparing a report on the current state of crowdfunding as an alternative means of financing. If you are interested in receiving this report, leave us your email address and we will send it to you once it has been prepared.